BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 12235266)

  • 1. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
    Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
    J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of cannabinoid CB1 receptors in improgan antinociception.
    Gehani NC; Nalwalk JW; Razdan RK; Martin BR; Sun X; Wentland M; Abood ME; Hough LB
    J Pain; 2007 Nov; 8(11):850-60. PubMed ID: 17644043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improgan-induced hypothermia: a role for cannabinoid receptors in improgan-induced changes in nociceptive threshold and body temperature.
    Salussolia CL; Nalwalk JW; Hough LB
    Brain Res; 2007 Jun; 1152():42-8. PubMed ID: 17433267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor.
    Meschler JP; Kraichely DM; Wilken GH; Howlett AC
    Biochem Pharmacol; 2000 Nov; 60(9):1315-23. PubMed ID: 11008125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
    Craft RM; Wakley AA; Tsutsui KT; Laggart JD
    J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-opioid antinociception produced by brain stem injections of improgan: significance of local, but not cross-regional, cannabinoid mechanisms.
    Hough LB; Svokos K; Nalwalk JW
    Brain Res; 2009 Jan; 1247():62-70. PubMed ID: 18983834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
    Sim-Selley LJ; Martin BR
    J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antinociceptive activity of chemical congeners of improgan: optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic.
    Hough LB; de Esch IJ; Janssen E; Phillips J; Svokos K; Kern B; Trachler J; Abood ME; Leurs R; Nalwalk JW
    Neuropharmacology; 2006 Sep; 51(3):447-56. PubMed ID: 16806300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid-improgan cross-tolerance: Improgan is a cannabinomimetic analgesic lacking affinity at the cannabinoid CB1 receptor.
    Nalwalk JW; Svokos K; Hough LB
    Eur J Pharmacol; 2006 Nov; 549(1-3):79-83. PubMed ID: 16989809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.
    Wagner JA; Járai Z; Bátkai S; Kunos G
    Eur J Pharmacol; 2001 Jul; 423(2-3):203-10. PubMed ID: 11448486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor.
    Fride E; Foox A; Rosenberg E; Faigenboim M; Cohen V; Barda L; Blau H; Mechoulam R
    Eur J Pharmacol; 2003 Feb; 461(1):27-34. PubMed ID: 12568912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one]-induced hypothermia.
    Rawls SM; Cabassa J; Geller EB; Adler MW
    J Pharmacol Exp Ther; 2002 Jun; 301(3):963-8. PubMed ID: 12023525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands.
    Smith SR; Terminelli C; Denhardt G
    Eur J Pharmacol; 2001 Aug; 425(1):73-83. PubMed ID: 11672577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats.
    Izzo AA; Mascolo N; Pinto L; Capasso R; Capasso F
    Eur J Pharmacol; 1999 Nov; 384(1):37-42. PubMed ID: 10611417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
    Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
    Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys.
    Wiley JL; Lowe JA; Balster RL; Martin BR
    J Pharmacol Exp Ther; 1995 Oct; 275(1):1-6. PubMed ID: 7562536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of SR141716A on G-protein activation in rat brain.
    Sim-Selley LJ; Brunk LK; Selley DE
    Eur J Pharmacol; 2001 Mar; 414(2-3):135-43. PubMed ID: 11239913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CC12, a high-affinity ligand for [3H]cimetidine binding, is an improgan antagonist.
    Hough LB; Nalwalk JW; Phillips JG; Kern B; Shan Z; Wentland MP; de Esch IJ; Janssen E; Barr T; Stadel R
    Neuropharmacology; 2007 Apr; 52(5):1244-55. PubMed ID: 17336343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A.
    Vivian JA; Kishioka S; Butelman ER; Broadbear J; Lee KO; Woods JH
    J Pharmacol Exp Ther; 1998 Aug; 286(2):697-703. PubMed ID: 9694923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding.
    Gómez R; Navarro M; Ferrer B; Trigo JM; Bilbao A; Del Arco I; Cippitelli A; Nava F; Piomelli D; Rodríguez de Fonseca F
    J Neurosci; 2002 Nov; 22(21):9612-7. PubMed ID: 12417686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.